Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Piperacillin-amikacin combinations: killing curves].

M Chanal1, J Sirot, C Chanal

  • 1Laboratoire de Bactériologie-Virologie, Faculté de Médecine, Clermont-Ferrand, France.

Pathologie-Biologie
|September 1, 1990
PubMed
Summary

The combination of piperacillin and amikacin demonstrated significant bactericidal activity against common Gram-negative bacteria. A lower dose combination proved effective in preventing bacterial regrowth, offering a promising therapeutic strategy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY Cohort.

Clinical lymphoma, myeloma & leukemia·2024
Same author

Alemtuzumab-induced immune-mediated thrombotic thrombocytopenic purpura: A newly described drug-related autoimmune disease.

British journal of haematology·2023
Same author

Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak.

The British journal of dermatology·2021
Same author

ALK7 expression in prolactinoma is associated with reduced prolactin and increased proliferation.

Endocrine-related cancer·2018
Same author

Quantitative-phase microscopy of nanosecond laser-induced micro-modifications inside silicon.

Applied optics·2016
Same author

Smoking cessation attempts: is it useful to treat hard core smokers?

Tobacco induced diseases·2016

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Piperacillin and amikacin are critical antibiotics for treating Gram-negative bacterial infections.
  • Understanding their combined bactericidal activity is essential for optimizing treatment regimens.
  • Evaluating activity against common clinical isolates like E. coli, K. pneumoniae, E. cloacae, and P. aeruginosa is crucial.

Purpose of the Study:

  • To evaluate the time-dependent bactericidal activity of piperacillin and amikacin, alone and in combination.
  • To assess the efficacy of different drug concentration combinations against various Gram-negative bacterial phenotypes.
  • To determine if combinations can prevent bacterial regrowth observed with monotherapy.

Main Methods:

  • Killing curves technique was employed to assess bactericidal activity over time.

Related Experiment Videos

  • Twenty-three clinical isolates of E. coli, K. pneumoniae, E. cloacae, and P. aeruginosa were tested.
  • Minimal inhibitory concentrations (MICs) for piperacillin ranged from 0.25 to 64 mg/L, and for amikacin from 1 to 8 mg/L.

    • Main Results:

    • Piperacillin (16 mg/L) combined with amikacin (8 mg/L) showed bactericidal effects against most strains (21/23) and prevented regrowth.
    • A low-dose combination of piperacillin (2 mg/L) and amikacin (4 mg/L) achieved bactericidal activity without regrowth for 9 strains.
    • High-dose combinations were required for bactericidal activity against Ticarcillin-resistant P. aeruginosa, which were bacteriostatic individually.

    Conclusions:

    • Piperacillin and amikacin combinations can enhance bactericidal activity and prevent bacterial regrowth.
    • Specific dose combinations, including lower ones, show significant potential against susceptible Gram-negative bacteria.
    • Combined therapy is essential for overcoming resistance, particularly in challenging pathogens like P. aeruginosa.